US FDA approves Sanofi's wearable injector form of blood cancer drug
10/07/2026 13:20
US FDA approves Sanofi's wearable injector form of blood cancer drug July 10 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Sanofi's SASY.PA blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple myeloma patients a less burdensome alternative to intravenous infusions.
(Reporting by Sneha S K in Bengaluru and Bhanvi Satija in London; Editing by Shreya Biswas)
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle